Andrea S. Pereyra

Andrea S. Pereyra

Auto-generated profile, based on publicly available information

Andrea S. Pereyra

Brody School of Medicine at East Carolina University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2023 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Open access
APAndrea S. Pereyra
Andrea S. Pereyra
KMKelsey L. McLaughlin
Kelsey L. McLaughlin
KBKatherine A. Buddo
Katherine A. Buddo
JEJessica M. Ellis
Jessica M. Ellis
This work demonstrates that the traditional concept of mitochondrial medium-chain fatty acid oxidation as unregulated and independent of carnitine applies only to liver metabolism, and to kidney to a lesser extent, but not the heart or skeletal muscle. Thus, the benefits of dietary medium-chain fatty acids are set by liver metabolic activity and peripheral tissues are unlikely to receive direct benefits from medium-chain fatty acid metabolism, but rather metabolic byproducts of liver’s medium-chain oxidative metabolism.

1 January 2021 in Journal of Lipid Research
Verified
Journal Article
Open access
APAndrea S. Pereyra
Andrea S. Pereyra
KHKate L. Harris
Kate L. Harris
Arvin Hendra SoepriatnaArvin Hendra Soepriatna
Arvin Hendra Soepriatna
QWQuin A. Waterbury
Quin A. Waterbury
SBSivakama S. Bharathi
Sivakama S. Bharathi
JEJessica M. Ellis
Jessica M. Ellis
Long-chain fatty acid oxidation is frequently impaired in primary and systemic metabolic diseases affecting the heart; thus, therapeutically increasing reliance on normally minor energetic substrates, such as ketones and medium-chain fatty acids, could benefit cardiac health. However, the molecular fundamentals of this therapy are not fully known. Here, we explored the ability of octanoate, an eight-carbon medium-chain fatty acid known as an unregulated mitochondrial energetic substrate, to ameliorate cardiac hypertrophy in long-chain fatty acid oxidation-deficient hearts because of carnitine palmitoyltransferase 2 deletion (Cpt2M-/-). CPT2 converts acylcarnitines to acyl-CoAs in the mitochondrial matrix for oxidative bioenergetic metabolism. In Cpt2M-/- mice, high octanoate-ketogenic diet failed to alleviate myocardial hypertrophy, dysfunction, and acylcarnitine accumulation suggesting that this alternative substrate is not sufficiently compensatory for energy provision. Aligning this outcome, we identified a major metabolic distinction between muscles and liver, wherein heart and skeletal muscle mitochondria were unable to oxidize free octanoate, but liver was able to oxidize free octanoate. Liver mitochondria, but not heart or muscle, highly expressed medium-chain acyl-CoA synthetases, potentially enabling octanoate activation for oxidation and circumventing acylcarnitine shuttling. Conversely, octanoylcarnitine was oxidized by liver, skeletal muscle, and heart, with rates in heart 4-fold greater than liver and, in muscles, was not dependent upon CPT2. Together, these data suggest that dietary octanoate cannot rescue CPT2-deficient cardiac disease. These data also suggest the existence of tissue-specific mechanisms for octanoate oxidative metabolism, with liver being independent of free carnitine availability, whereas cardiac and skeletal muscles depend on carnitine but not on CPT2.

4 June 2021 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
FDFrederick W. Damen
Frederick W. Damen
JSJohn P. Salvas
John P. Salvas
APAndrea S. Pereyra
Andrea S. Pereyra
JEJessica M. Ellis
Jessica M. Ellis
Craig GoergenCraig Goergen
Craig Goergen
Mouse models of cardiac disease have become essential tools in the study of pathological mechanisms, but the small size of rodents makes it challenging to quantify heart function with noninvasive imaging. Building off recent developments in high-frequency four-dimensional ultrasound (4DUS) imaging, we have applied this technology to study cardiac dysfunction progression in a murine model of metabolic cardiomyopathy. Cardiac knockout of carnitine palmitoyltransferase 2 (Cpt2M−/−) in mice hinders cardiomyocyte bioenergetic metabolism of long-chain fatty acids, and leads to progressive cardiac hypertrophy and heart failure. The proposed analysis provides a standardized approach to measure localized wall kinematics and simultaneously extracts metrics of global cardiac function, LV morphometry, regional circumferential strain, and regional longitudinal strain from an interpolated 4-D mesh of the endo- and epicardial boundaries. Comparison of metric changes due to aging suggests that circumferential strain at the base and longitudinal strain along the posterior wall are most sensitive to disease progression. We further introduce a novel hybrid strain index (HSI) that incorporates information from these two regions and may have greater utility to characterize disease progression relative to other extracted metrics. Potential applications to additional disease models are discussed that could further demonstrate the utility of metrics derived from 4DUS imaging and strain mapping. NEW & NOTEWORTHY High-frequency four-dimensional ultrasound can be used in conjunction with standardized analysis procedures to simultaneously extract left-ventricular global function, morphometry, and regional strain metrics. Furthermore, a novel hybrid strain index (HSI) formula demonstrates greater performance compared with all other metrics in characterizing disease progression in a model of metabolic cardiomyopathy.

7 April 2022 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
PRPablo Ranea-Robles
Pablo Ranea-Robles
NPNatalya N Pavlova
Natalya N Pavlova
ABAaron Bender
Aaron Bender
APAndrea S Pereyra
Andrea S Pereyra
JEJessica M. Ellis
Jessica M. Ellis
SHSander Michel Houten
Sander Michel Houten
Cardiomyopathy and arrhythmias can be severe presentations in patients with inherited defects of mitochondrial long-chain fatty acid β-oxidation (FAO). The pathophysiological mechanisms that underlie these cardiac abnormalities remain largely unknown. We investigated the molecular adaptations to a FAO deficiency in the heart using the long-chain acyl-CoA dehydrogenase (LCAD) knockout (KO) mouse model. We observed enrichment of amino acid metabolic pathways and of ATF4 target genes among the upregulated genes in the LCAD KO heart transcriptome. We also found a prominent activation of the eIF2α/ATF4 axis at the protein level that was independent of the feeding status, in addition to a reduction of cardiac protein synthesis during a short period of food withdrawal. These findings are consistent with an activation of the integrated stress response (ISR) in the LCAD KO mouse heart. Notably, charging of several transfer RNAs (tRNAs), such as tRNAGln was decreased in LCAD KO hearts, reflecting a reduced availability of cardiac amino acids, in particular, glutamine. We replicated the activation of the ISR in the hearts of mice with muscle-specific deletion of carnitine palmitoyltransferase 2. Our results show that perturbations in amino acid metabolism caused by long-chain FAO deficiency impact cardiac metabolic signalling, in particular the ISR. These results may serve as a foundation for investigating the role of the ISR in the cardiac pathology associated with long-chain FAO defects. Translational Perspective: The heart relies mainly on mitochondrial fatty acid β-oxidation (FAO) for its high energy requirements. The heart disease observed in patients with a genetic defect in this pathway highlights the importance of FAO for cardiac health. We show that the consequences of a FAO defect extend beyond cardiac energy homeostasis and include amino acid metabolism and associated signalling pathways such as the integrated stress response.

1 July 2026 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Open access
FJFilip Jevtovic
Filip Jevtovic
NWNicholas C. Williamson
Nicholas C. Williamson
APAndrea S. Pereyra
Andrea S. Pereyra
MAMolly K. Alexander
Molly K. Alexander
ESEspen E. Spangenburg
Espen E. Spangenburg
JEJessica M. Ellis
Jessica M. Ellis
Novel model of CACT loss in muscle to demonstrate that CACT is required for long, medium, and short-chain fatty acid oxidation in skeletal muscle. Deletion of CACT drives oxidative and glycolytic muscle lipid remodeling and impairs oxidative, but not glycolytic, muscle contractile capacity. Oxidative soleus muscle mitochondria compensate for CACT loss by increasing mitochondrial content and muscle capacity for oxidation of nonfatty acid substrates.